1/192
Looks like no tags are added yet.
Lipids
Heterogeneous group of organic substances, generally poorly soluble in water but soluble in nonpolar organic solvents.
Functions of lipids
• Energy storage and fuel.
• Structural components of cell membranes.
• Precursors of steroid hormones, bile acids and vitamin D.
• Disease link.
Blood plasma
90–92 % water — lipids form separate droplets instead of dissolving, so the body packages them into lipoproteins.
Lipoprotein structure
• Lipid core — fats (interior).
• Phospholipid surface — water-friendly (exterior).
• Apolipoproteins — "ID tags" on the surface; interact with enzymes, receptors and tissues.
Liver (lipid transport)
Processing and distribution center — produces, processes and clears many lipid-containing particles.
Simple lipids
Esters of fatty acids with alcohols: triglycerides, fats and oils, waxes.
Triacylglycerol
Triglyceride — one glycerol molecule attached to three fatty acids.
Fats and oils
The common storage forms of triglycerides in animals and plants.
Waxes
Esters of fatty acids with long-chain alcohols, rather than glycerol.
Compound lipids
Contain fatty acids and alcohol, with additional chemical groups such as phosphate or carbohydrate: phospholipids, glycolipids.
Glycolipid
Sugar residue attached to a lipid residue of the lipid membrane.
Derived lipids
Obtained from the breakdown or hydrolysis of simple or complex lipids, and related compounds: fatty acids, glycerol, cholesterol.
Glycerol
Derived lipid; can enter metabolic pathways for energy production or glucose synthesis.
Sterols
Subgroup of steroids with a hydroxyl (–OH) group and a characteristic four-ring structure; cholesterol is the major sterol in human tissues.
Saturated fatty acids
• Zero C=C double bonds.
• Relatively straight chains that pack closely together.
• Usually higher melting points than comparable unsaturated fatty acids.
• Example: stearic acid.
MUFA
Monounsaturated fatty acid — one C=C double bond; a cis double bond introduces a bend or kink.
PUFA
Polyunsaturated fatty acid — two or more C=C double bonds; several cis bends reduce tight packing; generally lower melting points than comparable saturated fatty acids.
Cis double bond
Both hydrogens on the same side of the hydrocarbon chain — causes a kink (cis oleic acid).
Trans double bond
Hydrogens on opposite sides of the hydrocarbon chain (trans oleic acid).
Major lipids in the body
Fatty acids, triglycerides, phospholipids, cholesterol.
Fatty acid
Chain of carbon atoms, each carrying hydrogens, with an acid group (–COOH) at one end.
Fatty acids
• Primary form of stored energy, held as triglycerides in adipose tissue.
• Come from the diet and from hepatic conversion of excess glucose.
• Excessive mobilization → excess acetyl-CoA.
Free fatty acids
Unesterified fatty acids — bound to albumin.
Esterified fatty acids
Carboxyl group linked by an ester bond in TAG, phospholipids and cholesteryl esters — the bulk of body and circulating fatty acids.
Triglycerides
• Three fatty acids ester-bonded to one glycerol.
• About 95 % of adipose tissue; the body's main storage form of fat.
• Neutral, water-insoluble lipids.
• By-product: ketone bodies.
• Carriers: CM, VLDL.
Triglycerides after absorption
Resynthesized in intestinal cells, then combined with other lipids and apoB-48 to form chylomicrons.
TAG fasting requirement
10–12 hours.
TAG peak after meals
4–6 hours.
Non-fasting TAG
Chylomicrons — dietary triglycerides from the intestine.
Fasting TAG
VLDL — triglycerides produced and released by the liver.
Clear specimen
TAG <200 mg/dL.
Hazy / turbid specimen
TAG >400 mg/dL.
Opaque / milky specimen
TAG >600 mg/dL.
Normal TAG
<150 mg/dL.
Borderline high TAG
150–199 mg/dL.
High TAG
200–499 mg/dL (NCEP). (The adult reference table prints high risk as 200–249 mg/dL.)
Very high TAG
≥500 mg/dL.
Phospholipids
• Two fatty acids attached to one glycerol (ester bonds), plus a phosphate group.
• Most abundant lipid in the body.
• Amphipathic.
• Synthesized in the cytosol of all organs, especially the liver.
Amphipathic
Having both water-loving and fat-loving parts — e.g. a phospholipid's hydrophilic head and hydrophobic tails.
Phospholipid head and tails
Hydrophilic head: phosphate + glycerol. Hydrophobic tails: fatty acids (saturated, unsaturated).
Lecithin
Phosphatidylcholine — 70 % of phospholipids; the most common phospholipid in lipoproteins and membranes.
Sphingomyelin
20 % of phospholipids; derived from sphingosine; Niemann-Pick disease.
Cephalin
10 % of phospholipids.
Cholesterol
• Sterol with four fused carbon rings.
• Precursor of steroids, bile acids and vitamin D; converted to bile salts.
• Carriers: HDL, LDL.
• Least affected by fasting status.
Cholesterol origin
Animal sterol, synthesized in our bodies; plants make phytosterols instead. (Lecture prints: "Synthesized in animals, plants, and our bodies".)
Free cholesterol
• Has a free hydroxyl group.
• Location: cell membranes and lipoprotein surface.
• Has a small polar region.
Cholesteryl ester
• Fatty acid attached to cholesterol.
• Location: lipoprotein core and intracellular stores.
• More hydrophobic.
LCAT
Lecithin–cholesterol acyltransferase — esterifies cholesterol in plasma (free cholesterol → cholesteryl esters); activated by apoA-I.
ACAT
Acyl-CoA:cholesterol acyltransferase — esterifies cholesterol inside cells for storage.
Esterification
Unesterified → esterified: free cholesterol attaches to a fatty acid, forming cholesteryl ester.
Saponification
Esterified → unesterified: cholesteryl ester is broken down into free cholesterol and a fatty acid.
Desirable cholesterol
<200 mg/dL.
Borderline / moderate cholesterol
200–239 mg/dL.
High cholesterol
≥240 mg/dL.
NCEP CHD risk, age 2–19
Cholesterol: moderate risk >170, high risk >185 mg/dL.
NCEP CHD risk, age 20–29
Cholesterol: moderate risk >200, high risk >220 mg/dL.
NCEP CHD risk, age 30–39
Cholesterol: moderate risk >220, high risk >240 mg/dL.
NCEP CHD risk, age >40
Cholesterol: moderate risk >240, high risk >260 mg/dL.
Digestive phase
• Begins with chewing and swallowing.
• Stomach: acid and gastric lipase (especially in infants).
• Pancreas: pancreatic lipase + colipase.
• Liver and gallbladder: bile salts emulsify fats.
• TAG → monoglycerides, diglycerides and free fatty acids; cholesterol + bile salts → micelle.
Absorptive phase
In the small intestine, micelles are absorbed; inside the enterocyte, triglycerides and cholesterol are re-esterified (reassembled).
Transport phase
• Long-chain fatty acids reassemble into chylomicrons → lymphatic system (lacteals) → thoracic duct → bloodstream.
• Short-chain fatty acids (≤12 carbons) enter the blood directly, bound to albumin, to all tissues including adipose.
Micelle
Cholesterol, fatty acids and monoglycerides surrounded by bile salts — the package absorbed by the small intestine.
Gastric lipase
Secreted with acid in the stomach; especially in infants.
Lipoproteins
• Macromolecular complexes of lipids and proteins that transport hydrophobic lipids through aqueous body fluids, particularly plasma.
• Size correlates with lipid content.
• Outer layer of proteins: the apolipoproteins.
Apolipoproteins
• Protein components of lipoproteins.
• Maintain the particle's structure.
• Activate enzymes that break down triglycerides.
• Help the particle bind to receptors so tissues or the liver can take it up.
• Amphipathic.
Chylomicrons
Largest and least dense; highest amount of fat.
Chylomicrons
Formed: intestines. Route: mesenteric lymphatics (lacteals) → blood at the thoracic duct.
Chylomicrons
Apo: B-48 (major), A-I, A-IV, C-I, C-II, C-III, E.
Chylomicrons
Appearance: opaque / turbid / creamy layer (before and after standing).
Chylomicrons
Time scale: half-life only minutes; cleared within 6–9 hours postprandial; (+) CM after a 12-hour fast = ABNORMAL.
Chylomicrons
Atherogenic: NO. Electrophoresis: remain at the origin.
VLDL
Pre-β lipoprotein; most insoluble. Formed: liver.
VLDL
Route: transports triglycerides made or assembled by the liver to peripheral tissues.
VLDL
Apo: B-100, with C-I, C-II, C-III and E.
VLDL
Appearance: turbid serum (before and after standing).
VLDL
Composition: TAG 65 %, cholesterol 16–27 %, phospholipid 15–20 %, protein 6–10 %. (The VLDL profile prints 50 % TAG, 40 % cholesterol, 10 % protein.)
VLDL
Production increased by: excess carbohydrate, saturated fat, trans fat.
IDL
Equal amounts of cholesterol, TAG and phospholipids; lipid content, size and density between VLDL and LDL; minor lipoprotein; can be converted to β-VLDL.
IDL
Formed from VLDL metabolism. Apo: C, E, B-100.
IDL fates
• Cleared by the liver with the help of apoE.
• Further TAG removal and remodelling (loses apoE; hepatic lipase) → LDL.
LDL
β-lipoprotein. Delivers cholesterol to peripheral cells and the liver following triglyceride removal.
LDL
Most cholesterol-rich lipoprotein; most abundant lipoprotein (50 %); primary marker for CHD; MOST atherogenic.
LDL
Formed from VLDL remodelling.
Fate: tissue delivery or hepatic clearance — the liver takes up ~70 % through LDL receptors; other tissues use it for membrane or steroid hormone synthesis, or it is deposited.
LDL
Apo: B-100 only. (Lecture prints: "Apo C, Apo E, Apo B100".)
LDL
Composition: cholesterol 50 %, protein 25 %, phospholipid 20 %, TAG 5 %.
LDL vs LDL-C
LDL is the lipoprotein particle; LDL-C is the amount of cholesterol carried within LDL particles.
Optimal LDL
<100 mg/dL.
Near optimal LDL
100–129 mg/dL.
Borderline high LDL
130–159 mg/dL.
High LDL
160–189 mg/dL.
Very high LDL
≥190 mg/dL.
Statin therapy
Recommended for a person with multiple risk factors and LDL ≥100 mg/dL; optimum LDL for such individuals is <70 mg/dL.
Lp(a)
LDL particle with an extra protein tail attached. Apo: B-100, apo(a). Formed: liver.
Lp(a)
Sinking pre-β lipoprotein; minor lipoprotein.
Lp(a)
Independent, causal risk factor for atherosclerotic cardiovascular disease; proatherogenic; prothrombotic / antifibrinolytic.
HDL
Reverse cholesterol transport — carries excess cholesterol from tissues back to the liver.
HDL
Smallest but densest; smallest total amount of fat; α-lipoprotein.
HDL
Formed: liver and small intestine. Apo: C, E, A-II, A-I.
HDL
Removes cholesterol from the arterial wall — inverse relationship with CHD risk.
HDL reference method
Ultracentrifugation, heparin–manganese precipitation, Abell-Kendall assay.